litlas
ログインアカウント作成

Joseph P. Eder

1986–2024 年に発表

55
論文数
21,710
被引用数
43
h 指数
55
i10 指数

被引用数

Joseph P. Eder の年別被引用数1986 年: 被引用 1 件1987 年: 被引用 2 件1988 年: 被引用 6 件1989 年: 被引用 6 件1990 年: 被引用 2 件1991 年: 被引用 1 件1992 年: 被引用 7 件1993 年: 被引用 5 件1994 年: 被引用 9 件1995 年: 被引用 19 件1996 年: 被引用 8 件1997 年: 被引用 9 件1998 年: 被引用 6 件1999 年: 被引用 8 件2000 年: 被引用 12 件2001 年: 被引用 9 件2002 年: 被引用 10 件2003 年: 被引用 16 件2004 年: 被引用 30 件2005 年: 被引用 32 件2006 年: 被引用 40 件2007 年: 被引用 37 件2008 年: 被引用 38 件2009 年: 被引用 47 件2010 年: 被引用 57 件2011 年: 被引用 59 件2012 年: 被引用 56 件2013 年: 被引用 48 件2014 年: 被引用 55 件2015 年: 被引用 219 件2016 年: 被引用 514 件2017 年: 被引用 650 件2018 年: 被引用 538 件2019 年: 被引用 1,353 件2020 年: 被引用 1,341 件2021 年: 被引用 1,129 件2022 年: 被引用 820 件2023 年: 被引用 566 件2024 年: 被引用 783 件2025 年: 被引用 355 件2026 年: 被引用 5 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,411 件、この内訳の 26.7%中国: 引用元論文 1,984 件、この内訳の 15.5%イギリス: 引用元論文 615 件、この内訳の 4.8%ドイツ: 引用元論文 586 件、この内訳の 4.6%イタリア: 引用元論文 572 件、この内訳の 4.5%フランス: 引用元論文 548 件、この内訳の 4.3%日本: 引用元論文 548 件、この内訳の 4.3%スペイン: 引用元論文 404 件、この内訳の 3.2%カナダ: 引用元論文 389 件、この内訳の 3%韓国: 引用元論文 356 件、この内訳の 2.8%オーストラリア: 引用元論文 310 件、この内訳の 2.4%オランダ: 引用元論文 303 件、この内訳の 2.4%
0%26.7%その他 21.5%

機関

分野

  • Medicine76.1%
  • Biochemistry, Genetics and Molecular Biology13.1%
  • Immunology and Microbiology7.4%
  • Engineering0.9%
  • Neuroscience0.5%
  • Materials Science0.3%
  • その他1.7%

トピック

  • Cancer Immunotherapy and Biomarkers19.5%
  • Immunotherapy and Immune Responses6.2%
  • Lung Cancer Treatments and Mutations4.3%
  • CAR-T cell therapy research4.2%
  • Lung Cancer Research Studies3.7%
  • Immune Cell Function and Interaction3.4%
  • その他58.7%

共著者

全論文

検索で開く
  1. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

    著者: Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi - New England Journal of Medicine 2015 被引用: 6,228

  2. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

    著者: Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra, Jared Weiss, Raanan Berger, Joseph P. Eder, Karl Heath, Terrill K. McClanahan, Jared Lunceford, Christine K. Gause, Jonathan D. Cheng, Laura Q.M. Chow - The Lancet Oncology 2016 被引用: 1,740

  3. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

    著者: Leisha A. Emens, Cristina Cruz, Joseph P. Eder, Fadi Braiteh, Cathie T. Chung, Sara M. Tolaney, Irene Kuter, Rita Nanda, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Ehab A. ElGabry, Ching-Wei Chang, Indrani Sarkar, William Grossman, Carol O’Hear, Marcella Fassò, Luciana Molinero, Peter Schmid - JAMA Oncology 2018 被引用: 793

  4. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    著者: Thomas Powles, Joseph P. Eder, Gregg Fine, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz, Joaquim Bellmunt, Howard A. Burris, Daniel P. Petrylak, Siew-leng Melinda Teng, Xiaodong Shen, Zachary Boyd, Priti S. Hegde, Daniel S. Chen, Nicholas J. Vogelzang - Nature 2014 被引用: 2,430

  5. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    著者: Scott Antonia, José A. López-Martín, Johanna C. Bendell, Patrick A. Ott, Matthew H. Taylor, Joseph P. Eder, Dirk Jäger, M. Catherine Pietanza, Dung T. Le, Filippo de Braud, Michael A. Morse, Paolo A. Ascierto, Leora Horn, Asim Amin, Rathi N. Pillai, Jeffry Evans, Ian Chau, Petri Bono, Akin Atmaca, Padmanee Sharma, Christopher Harbison, Chen-Sheng Lin, Olaf Christensen, Emiliano Calvo - The Lancet Oncology 2016 被引用: 1,254

  6. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

    著者: Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Ravit Geva, Hyun Cheol Chung, Chia‐Chi Lin, Deepti Aurora-Garg, Archana Ray, Kumudu Pathiraja, Jonathan D. Cheng, Laura Q.M. Chow, Robert I. Haddad - British Journal of Cancer 2018 被引用: 456

  7. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

    著者: Kei Muro, Hyun Cheol Chung, Veena Shankaran, Ravit Geva, Daniel V.T. Catenacci, Shilpa Gupta, Joseph P. Eder, Talia Golan, Dung T. Le, Barbara Burtness, Autumn J. McRee, Chia‐Chi Lin, Kumudu Pathiraja, Jared Lunceford, Kenneth Emancipator, Jonathan Juco, Minori Koshiji, Yung‐Jue Bang - The Lancet Oncology 2016 被引用: 1,131

  8. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

    著者: Carlos Gomez‐Roca, Philippe A. Cassier, Dmitriy Zamarin, Jean‐Pascal Machiels, José Luis Perez‐Gracia, F. Stephen Hodi, Álvaro Taus, Maria Martinez‐García, Valentina Boni, Joseph P. Eder, Navid Hafez, Ryan J. Sullivan, David F. McDermott, Stéphane Champiat, Sandrine Aspeslagh, C. Terret, Anna-Maria Jegg, Wolfgang Jacob, Michael A. Cannarile, Carola H. Ries, Konstanty Korski, Francesca Michielin, R D Christen, Galina Babitzki, Carl Watson, Georgina Meneses‐Lorente, Maja Weisser, Dominik Rüttinger, Jean‐Pierre Delord, Aurélien Marabelle - Journal for ImmunoTherapy of Cancer 2022 被引用: 104

  9. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    著者: Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph P. Eder, Barbara Burtness, Se‐Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia‐Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled‐Filhart, Kumudu Pathiraja, Jonathan D. Cheng, Tanguy Y. Seiwert - Journal of Clinical Oncology 2016 被引用: 859

  10. A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

    著者: David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer J. Wheler, Donald P. Lawrence, Joseph P. Eder, Colin J. Meyer, Deborah A. Ferguson, James W. Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Küfe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube - Clinical Cancer Research 2012 被引用: 232

  11. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

    著者: Neal Ready, Anna F. Farago, Filippo de Braud, Akin Atmaca, Matthew D. Hellmann, Jeffrey Schneider, David R. Spigel, Víctor Moreno, Ian Chau, Christine L. Hann, Joseph P. Eder, Nicola Steele, Anne Pieters, Justin Fairchild, Scott Antonia - Journal of Thoracic Oncology 2018 被引用: 378

  12. Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors

    著者: Anna Berkenblit, Joseph P. Eder, David P. Ryan, Michael V. Seiden, Noriaki Tatsuta, Matthew L. Sherman, Thomas Dahl, Bruce J. Dezube, Jeffrey G. Supko - Clinical Cancer Research 2007 被引用: 120

  13. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

    著者: Rina Hui, Edward B. Garon, J.W. Goldman, Natasha B. Leighl, Matthew D. Hellmann, Amita Patnaik, Leena Gandhi, Joseph P. Eder, Myung‐Ju Ahn, Leora Horn, Enriqueta Felip, Enric Carcereny, Reshma Rangwala, Gregory M. Lubiniecki, J. Zhang, Kenneth Emancipator, Charlotte Roach, Naiyer A. Rizvi - Annals of Oncology 2017 被引用: 235

  14. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

    著者: Geoffrey I. Shapiro, Patricia LoRusso, Afshin Dowlati, T. Khanh, Caron A. Jacobson, Ulka N. Vaishampayan, Amy Weise, Paolo F. Caimi, Joseph P. Eder, Christopher A. French, Emily Labriola–Tompkins, Frédéric Boisserie, William E. Pierceall, Jianguo Zhi, Sharon Passe, Mark DeMario, Martin Kornacker, Philippe Armand - British Journal of Cancer 2020 被引用: 119

  15. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

    著者: Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Andrew Albright, Robin Mogg, Mark Ayers, Lingkang Huang, Jared Lunceford, Răzvan Cristescu, Jonathan D. Cheng, Ranee Mehra - Journal for ImmunoTherapy of Cancer 2022 被引用: 96

  16. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)

    著者: Haider Mahdi, Navid Hafez, Deborah B. Doroshow, Davendra Sohal, Vickie L. Keedy, T. Khanh, Patricia LoRusso, Juliane M. Jürgensmeier, Manuel Avedissian, Jeffrey Sklar, Colin P. Glover, Brunella Felicetti, Emma Dean, Peter G. Mortimer, Geoffrey I. Shapiro, Joseph P. Eder - JCO Precision Oncology 2021 被引用: 69

  17. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    著者: Neil H. Segal, Ignacio Melero, Víctor Moreno, Neeltje Steeghs, Aurélien Marabelle, Kristoffer Staal Rohrberg, María E. Rodríguez-Ruiz, Joseph P. Eder, Cathy Eng, Gulam A. Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C. Elze, Hartmut Koeppen, Candice Jamois, Meret Martin‐Facklam, Christopher H. Lieu, Emiliano Calvo, Luis Paz‐Ares, Josep Tabernero, Guillem Argilés - Nature Communications 2024 被引用: 60

  18. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop

    著者: Guy T. Clifton, Mace L. Rothenberg, Paolo A. Ascierto, Glenn Begley, Michael Cecchini, Joseph P. Eder, François Ghiringhelli, Antoîne Italiano, Marina Kochetkova, Rong Li, Fatima Mechta‐Grigoriou, Sara I. Pai, Paolo P. Provenzano, Ellen Puré, Antoni Ribas, Kurt A. Schalper, Wolf H. Fridman - Journal for ImmunoTherapy of Cancer 2023 被引用: 40

  19. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

    著者: Natasha B. Leighl, Matthew D. Hellmann, Rina Hui, Enric Carcereny, Enriqueta Felip, Myung‐Ju Ahn, Joseph P. Eder, Ani Sarkis Balmanoukian, Charu Aggarwal, Leora Horn, Amita Patnaik, Matthew A. Gubens, Suresh S. Ramalingam, Gregory M. Lubiniecki, Jin Zhang, Bilal Piperdi, Edward B. Garon - The Lancet Respiratory Medicine 2019 被引用: 182

  20. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).

    著者: Josep Tabernero, Ignacio Melero, Willeke Ros, Guillem Argilés, Aurélien Marabelle, María E. Rodríguez-Ruiz, Joan Albanell, Emiliano Calvo, Víctor Moreno, James M. Cleary, Joseph P. Eder, Vaios Karanikas, Said Bouseida, Federico Sandoval, Daniel Sabanes, Sasha Sreckovic, Herbert I. Hurwitz, Luis Paz‐Ares, Jose M. Saro Suarez, Neil H. Segal - Journal of Clinical Oncology 2017 被引用: 168

  21. A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

    著者: Joaquı́n Mateo, Gopinath Ganji, Charlotte Lemech, Howard A. Burris, Sae‐Won Han, Karen E. Swales, Shaun Decordova, M. Phillip DeYoung, Deborah A. Smith, Shanker Kalyana‐Sundaram, Jiuhua Wu, Monica Motwani, Rakesh Kumar, Jerry M. Tolson, Sun Young Rha, Hyun Cheol Chung, Joseph P. Eder, Sunil Sharma, Yung‐Jue Bang, Jeffrey R. Infante, Yan Li, Johann S. de Bono, Hendrik-Tobias Arkenau - Clinical Cancer Research 2017 被引用: 143

  22. A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

    著者: Joseph P. Eder, Geoffrey I. Shapiro, Leonard J. Appleman, Andrew X. Zhu, Dale Miles, Harold Keer, Belinda Cancilla, Felix Chu, Suzanne Hitchcock‐Bryan, Laurie Sherman, Stewart W. McCallum, Elisabeth I. Heath, Scott A. Boerner, Patricia LoRusso - Clinical Cancer Research 2010 被引用: 193

  23. Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)

    著者: Evanthia T. Roussos Torres, Christine I. Rafie, Chenguang Wang, David Lim, Adam Brufsky, Patricia LoRusso, Joseph P. Eder, Vincent Chung, Melinda Downs, Molly Geare, Richard Piekarz, Howard Streicher, Leslie Anforth, Michelle A. Rudek, Qingfeng Zhu, Sepideh Besharati, Ashley Cimino‐Mathews, Robert A. Anders, Vered Stearns, Elizabeth M. Jaffee, Roisín M. Connolly - Clinical Cancer Research 2021 被引用: 35

  24. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers

    著者: Joyce F. Liu, Michael S. Gordon, Jennifer Veneris, Fadi Braiteh, Ani Sarkis Balmanoukian, Joseph P. Eder, Ana Oaknin, Erika Hamilton, Yulei Wang, Indrani Sarkar, Luciana Molinero, Marcella Fassò, Carol O’Hear, Yvonne G. Lin, Leisha A. Emens - Gynecologic Oncology 2019 被引用: 137